MedTrace Logo

Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

NCT00420680 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-08-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of 2.0 mg/kg and 4.0 mg/kg sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium in cardiac patients

Conditions

  • Anesthesia

Interventions

DRUG

Sugammadex

Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium

DRUG

Sugammadex

Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.

DRUG

Placebo

Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-07
Primary Completion
2006-08-01
Completion
2006-08-01

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420680 on ClinicalTrials.gov